Works by Lee, Ki Hyeong

Results: 68
    1

    Real-world outcomes of anti-PD1 antibodies in platinum-refractory, PD-L1-positive recurrent and/or metastatic non-small cell lung cancer, and its potential practical predictors: first report from Korean Cancer Study Group LU19-05.

    Published in:
    Journal of Cancer Research & Clinical Oncology, 2021, v. 147, n. 8, p. 2459, doi. 10.1007/s00432-021-03527-4
    By:
    • Park, Ji Hyun;
    • You, Gun Lyung;
    • Ahn, Myung-Ju;
    • Kim, Sang-We;
    • Hong, Min Hee;
    • Han, Ji-Youn;
    • Ock, Chan-Young;
    • Lee, Jong-Seok;
    • Oh, In Jae;
    • Lee, Shin Yup;
    • Kim, Cheol Hyeon;
    • Min, Young Joo;
    • Choi, Yoon Hee;
    • Ryu, Jeong-Seon;
    • Park, Sun Hyo;
    • Ahn, Hee Kyung;
    • Shim, Byoung-Yong;
    • Lee, Ki Hyeong;
    • Lee, Sung Yong;
    • Kim, Jin-Soo
    Publication type:
    Article
    2

    First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression.

    Published in:
    Journal of Cancer Research & Clinical Oncology, 2019, v. 145, n. 6, p. 1569, doi. 10.1007/s00432-019-02862-x
    By:
    • Schuler, Martin;
    • Tan, Eng-Huat;
    • O'Byrne, Kenneth;
    • Zhang, Li;
    • Boyer, Michael;
    • Mok, Tony;
    • Hirsh, Vera;
    • Yang, James Chih-Hsin;
    • Lee, Ki Hyeong;
    • Lu, Shun;
    • Shi, Yuankai;
    • Kim, Sang-We;
    • Laskin, Janessa;
    • Kim, Dong-Wan;
    • Arvis, Catherine Dubos;
    • Kölbeck, Karl;
    • Massey, Dan;
    • Märten, Angela;
    • Paz-Ares, Luis;
    • Park, Keunchil
    Publication type:
    Article
    3
    4
    5
    6

    Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations.

    Published in:
    Drugs, 2021, v. 81, n. 2, p. 257, doi. 10.1007/s40265-020-01441-6
    By:
    • Mok, Tony S.;
    • Cheng, Ying;
    • Zhou, Xiangdong;
    • Lee, Ki Hyeong;
    • Nakagawa, Kazuhiko;
    • Niho, Seiji;
    • Chawla, Alka;
    • Rosell, Rafael;
    • Corral, Jesus;
    • Migliorino, Maria Rita;
    • Pluzanski, Adam;
    • Noonan, Kay;
    • Tang, Yiyun;
    • Pastel, Malaika;
    • Wilner, Keith D.;
    • Wu, Yi-Long
    Publication type:
    Article
    7

    A Prospective Multicenter Study Evaluating Secondary Adrenal Suppression After Antiemetic Dexamethasone Therapy in Cancer Patients Receiving Chemotherapy: A Korean South West Oncology Group Study.

    Published in:
    Oncologist, 2015, v. 20, n. 12, p. 1432, doi. 10.1634/theoncologist.2015-0211
    By:
    • Han, Hye Sook;
    • Park, Ji Chan;
    • Park, Suk Young;
    • Lee, Kyu Taek;
    • Bae, Sang Byung;
    • Kim, Han Jo;
    • Kim, Samyoung;
    • Yun, Hwan Jung;
    • Bae, Woo Kyun;
    • Shim, Hyun‐Jeong;
    • Hwang, Jun‐Eul;
    • Cho, Sang‐Hee;
    • Park, Moo‐Rim;
    • Shim, Hyeok;
    • Kwon, Jihyun;
    • Choi, Moon Ki;
    • Kim, Seung Taik;
    • Lee, Ki Hyeong
    Publication type:
    Article
    8

    Anakinra usage in febrile infection related epilepsy syndrome: an international cohort.

    Published in:
    Annals of Clinical & Translational Neurology, 2020, v. 7, n. 12, p. 2467, doi. 10.1002/acn3.51229
    By:
    • Lai, Yi‐Chen;
    • Muscal, Eyal;
    • Wells, Elizabeth;
    • Shukla, Nikita;
    • Eschbach, Krista;
    • Hyeong Lee, Ki;
    • Kaliakatsos, Marios;
    • Desai, Nevedita;
    • Wickström, Ronny;
    • Viri, Maurizio;
    • Freri, Elena;
    • Granata, Tiziana;
    • Nangia, Srishti;
    • Dilena, Robertino;
    • Brunklaus, Andreas;
    • Wainwright, Mark S.;
    • Gorman, Mark P.;
    • Stredny, Coral M.;
    • Asiri, Abdurhman;
    • Hundallah, Khalid
    Publication type:
    Article
    9
    10

    Analysis of Response and Progression Patterns of Tyrosine Kinase Inhibitors in Recurrent or Metastatic Adenoid Cystic Carcinoma: A Post Hoc Analysis of Two KCSG Phase II Trials.

    Published in:
    Cancer Research & Treatment, 2024, v. 56, n. 4, p. 1068, doi. 10.4143/crt.2024.008
    By:
    • Kim, Youjin;
    • Keam, Bhumsuk;
    • Kang, Eun Joo;
    • Kim, Jin-Soo;
    • Kim, Hye Ryun;
    • Lee, Keun-Wook;
    • Kwon, Jung Hye;
    • Lee, Kyoung Eun;
    • Yang, Yaewon;
    • Choi, Yoon Hee;
    • Kim, Min Kyoung;
    • Ji, Jun Ho;
    • Yun, Tak;
    • Choi, Moon Young;
    • Lee, Ki Hyeong;
    • Kim, Sung-Bae;
    • Ahn, Myung-Ju
    Publication type:
    Article
    11

    Lazertinib versus Gefitinib as First-Line Treatment for EGFR-Mutated Locally Advanced or Metastatic NSCLC: LASER301 Korean Subset.

    Published in:
    Cancer Research & Treatment, 2024, v. 56, n. 1, p. 48, doi. 10.4143/crt.2023.453
    By:
    • Ki Hyeong Lee;
    • Byoung Chul Cho;
    • Myung-Ju Ahn;
    • Yun-Gyoo Lee;
    • Youngjoo Lee;
    • Jong-Seok Lee;
    • Joo-Hang Kim;
    • Young Joo Min;
    • Gyeong-Won Lee;
    • Sung Sook Lee;
    • Kyung-Hee Lee;
    • Yoon Ho Ko;
    • Byoung Yong Shim;
    • Sang-We Kim;
    • Sang Won Shin;
    • Jin-Hyuk Choi;
    • Dong-Wan Kim;
    • Eun Kyung Cho;
    • Keon Uk Park;
    • Jin-Soo Kim
    Publication type:
    Article
    12
    13

    Real-World Experience of Nivolumab in Non-small Cell Lung Cancer in Korea.

    Published in:
    Cancer Research & Treatment, 2020, v. 52, n. 4, p. 1112, doi. 10.4143/crt.2020.245
    By:
    • Sun Min Lim;
    • Sang-We Kim;
    • Byoung Chul Cho;
    • Jin Hyung Kang;
    • Myung-Ju Ahn;
    • Dong-Wan Kim;
    • Young-Chul Kim;
    • Jin Soo Lee;
    • Jong-Seok Lee;
    • Sung Yong Lee;
    • Keon Uk Park;
    • Ho Jung An;
    • Eun Kyung Cho;
    • Tae Won Jang;
    • Bong-Seog Kim;
    • Joo-Hang Kim;
    • Sung Sook Lee;
    • Im-II Na;
    • Seung Soo Yoo;
    • Ki Hyeong Lee
    Publication type:
    Article
    14
    15

    Randomized Phase III Trial of Irinotecan Plus Cisplatin versus Etoposide Plus Cisplatin in Chemotherapy-Naïve Korean Patients with Extensive-Disease Small Cell Lung Cancer.

    Published in:
    Cancer Research & Treatment, 2019, v. 51, n. 1, p. 119, doi. 10.4143/crt.2018.019
    By:
    • Dong-Wan Kim;
    • Hoon-Gu Kim;
    • Joo-Hang Kim;
    • Keunchil Park;
    • Hoon-Kyo Kim;
    • Joung Soon Jang;
    • Bong-Seog Kim;
    • Jin-Hyoung Kang;
    • Kyung Hee Lee;
    • Sang-We Kim;
    • Hun Mo Ryoo;
    • Jin-Soo Kim;
    • Ki Hyeong Lee;
    • Jung Hye Kwon;
    • Jin-Hyuk Choi;
    • Sang Won Shin;
    • Seokyung Hahn;
    • Dae Seog Heo
    Publication type:
    Article
    16
    17
    18

    Feasibility and Efficacy of Eribulin Mesilate in Korean Patients with Metastatic Breast Cancer: Korean Multi-center Phase IV Clinical Study Results.

    Published in:
    Cancer Research & Treatment, 2017, v. 49, n. 2, p. 423, doi. 10.4143/crt.2016.191
    By:
    • Yeon Hee Park;
    • Tae Yong Kim;
    • Young-Hyuck Im;
    • Keun-Seok Lee;
    • In Hae Park;
    • Joohyuk Sohn;
    • Soo-Hyeon Lee;
    • Seock-Ah Im;
    • Jee Hyun Kim;
    • Se Hyun Kim;
    • Soo Jung Lee;
    • Su-Jin Koh;
    • Ki Hyeong Lee;
    • Yoon Ji Choi;
    • Eun Kyung Cho;
    • Suee Lee;
    • Seok Yun Kang;
    • Jae Hong Seo;
    • Sung-Bae Kim;
    • Kyung Hae Jung
    Publication type:
    Article
    19
    20
    21
    22
    23
    24
    25
    26
    27
    28
    29

    Molecular alterations and poziotinib efficacy, a pan‐HER inhibitor, in human epidermal growth factor receptor 2 (HER2)‐positive breast cancers: Combined exploratory biomarker analysis from a phase II clinical trial of poziotinib for refractory HER2‐positive breast cancer patients

    Published in:
    International Journal of Cancer, 2019, v. 145, n. 6, p. 1669, doi. 10.1002/ijc.32188
    By:
    • Kim, Ji‐Yeon;
    • Lee, Eunjin;
    • Park, Kyunghee;
    • Jung, Hae Hyun;
    • Park, Woong‐Yang;
    • Lee, Kyung‐Hun;
    • Sohn, Joohyuk;
    • Lee, Keun Seok;
    • Jung, Kyung Hae;
    • Kim, Jee Hyun;
    • Lee, Ki Hyeong;
    • Im, Seock‐Ah;
    • Park, Yeon Hee
    Publication type:
    Article
    30

    A phase II trial of the pan‐HER inhibitor poziotinib, in patients with HER2‐positive metastatic breast cancer who had received at least two prior HER2‐directed regimens: results of the NOV120101‐203 trial.

    Published in:
    International Journal of Cancer, 2018, v. 143, n. 12, p. 3240, doi. 10.1002/ijc.31651
    By:
    • Park, Yeon Hee;
    • Lee, Kyung‐Hun;
    • Sohn, Joo Hyuk;
    • Lee, Keun Seok;
    • Jung, Kyung Hae;
    • Kim, Jee‐Hyun;
    • Lee, Ki Hyeong;
    • Ahn, Jin Seok;
    • Kim, Tae‐Yong;
    • Kim, Gun Min;
    • Park, In Hae;
    • Kim, Sung‐Bae;
    • Kim, Se Hyun;
    • Han, Hye Sook;
    • Im, Young‐Hyuck;
    • Ahn, Jin‐Hee;
    • Kim, Jung‐Yong;
    • Kang, Jahoon;
    • Im, Seock‐Ah
    Publication type:
    Article
    31
    32
    33
    34
    35

    First‐line nivolumab, paclitaxel, carboplatin, and bevacizumab for advanced non‐squamous non‐small cell lung cancer: Updated survival analysis of the ONO‐4538‐52/TASUKI‐52 randomized controlled trial.

    Published in:
    Cancer Medicine, 2023, v. 12, n. 16, p. 17061, doi. 10.1002/cam4.6348
    By:
    • Kim, Hye Ryun;
    • Sugawara, Shunichi;
    • Lee, Jong‐Seok;
    • Kang, Jin‐Hyoung;
    • Inui, Naoki;
    • Hida, Toyoaki;
    • Lee, Ki Hyeong;
    • Yoshida, Tatsuya;
    • Tanaka, Hiroshi;
    • Yang, Cheng‐Ta;
    • Nishio, Makoto;
    • Ohe, Yuichiro;
    • Tamura, Tomohide;
    • Yamamoto, Nobuyuki;
    • Yu, Chong‐Jen;
    • Akamatsu, Hiroaki;
    • Takahashi, Shigeru;
    • Nakagawa, Kazuhiko
    Publication type:
    Article
    36
    37
    38

    Gefitinib versus pemetrexed as second-line treatment in patients with nonsmall cell lung cancer previously treated with platinum-based chemotherapy (KCSG-LU08-01).

    Published in:
    Cancer (0008543X), 2012, v. 118, n. 24, p. 6234, doi. 10.1002/cncr.27630
    By:
    • Sun, Jong-Mu;
    • Lee, Ki Hyeong;
    • Kim, Sang-we;
    • Lee, Dae Ho;
    • Min, Young Joo;
    • Yun, Hwan Jung;
    • Kim, Hoon Kyo;
    • Song, Hong Suk;
    • Kim, Yeul Hong;
    • Kim, Bong-Seog;
    • Hwang, In Gyu;
    • Lee, Keehyun;
    • Jo, Sook Jung;
    • Lee, Jae Won;
    • Ahn, Jin Seok;
    • Park, Keunchil;
    • Ahn, Myung-Ju
    Publication type:
    Article
    39
    40
    41
    42
    43
    44

    Clinical trial of nintedanib in patients with recurrent or metastatic salivary gland cancer of the head and neck: A multicenter phase 2 study (Korean Cancer Study Group HN14-01).

    Published in:
    2017
    By:
    • Kim, Youjin;
    • Lee, Su Jin;
    • Lee, Ji Yun;
    • Lee, Se‐Hoon;
    • Sun, Jong‐Mu;
    • Park, Keunchil;
    • An, Ho Jung;
    • Cho, Jae Yong;
    • Kang, Eun Joo;
    • Lee, Ha‐Young;
    • Kim, Jinsoo;
    • Keam, Bhumsuk;
    • Kim, Hye Ryun;
    • Lee, Kyoung Eun;
    • Choi, Moon Young;
    • Lee, Ki Hyeong;
    • Ahn, Myung‐Ju;
    • Lee, Se-Hoon;
    • Sun, Jong-Mu;
    • Lee, Ha-Young
    Publication type:
    journal article
    45
    46
    47
    48

    Orthostatic paroxysmal dystonia.

    Published in:
    Movement Disorders, 2002, v. 17, n. 4, p. 841, doi. 10.1002/mds.10182
    By:
    • Sethi, Kapil D.;
    • Lee, Ki Hyeong;
    • Deuskar, Vasanti;
    • Hess, David C.
    Publication type:
    Article
    49

    Anthropometric measurements and survival after a prostate cancer diagnosis.

    Published in:
    2018
    By:
    • Sun, Jong-Mu;
    • Lee, Ki Hyeong;
    • Kim, Bong-Seog;
    • Kim, Hoon-Gu;
    • Min, Young Joo;
    • Yi, Seong Yoon;
    • Yun, Hwan Jung;
    • Jung, Sin-Ho;
    • Lee, Se-Hoon;
    • Ahn, Jin Seok;
    • Park, Keunchil;
    • Ahn, Myung-Ju;
    • Farris, Megan S;
    • Courneya, Kerry S;
    • Kopciuk, Karen A;
    • McGregor, S Elizabeth;
    • Friedenreich, Christine M
    Publication type:
    journal article
    50